Side Effects of ubrogepant: A Synthesis of Findings from 9 Studies

  1. Home
  2. Side Effects of ubrogepant
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of ubrogepant: A Synthesis of Findings from 9 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of ubrogepant: A Synthesis of Findings from 9 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Ubrogepant is an effective treatment for acute migraines, according to several clinical trials. 7 Ubrogepant is a selective antagonist of the calcitonin gene-related peptide (CGRP) receptor, which is believed to block the development of migraines. 9 Compared to a placebo, ubrogepant has been shown to have a higher proportion of patients who have pain relief within two hours and is generally well tolerated. 7 Ubrogepant has also been shown to have a lower risk of hepatotoxicity compared to other migraine treatments. 5 However, the long-term safety of ubrogepant is still being investigated. 1

Reasons for Side Effects

The side effects of ubrogepant are believed to be caused by its antagonistic action on the CGRP receptor. CGRP is a neurotransmitter involved in vasodilation and inflammatory reactions, and it also plays a role in the development of migraines. When ubrogepant inhibits the CGRP receptor, it suppresses these reactions, which helps to alleviate the symptoms of migraine. However, CGRP is also present in other tissues and organs, and the action of ubrogepant may affect the functions of these tissues and organs. This is thought to be the cause of ubrogepant side effects.

Common Side Effects

Oropharyngeal Pain

The most common side effect of ubrogepant is oropharyngeal pain. 7 This is believed to be caused by the inhibition of CGRP receptors by ubrogepant, which suppresses vasodilation and inflammation in the oropharynx.

Nasopharyngitis

Nasopharyngitis is another reported side effect of ubrogepant. 7 This is thought to be caused by the inhibition of CGRP receptors by ubrogepant, which suppresses vasodilation and inflammation in the nasopharynx.

Headache

Headache has been reported as a side effect of ubrogepant. 7 This is thought to be caused by ubrogepant's inhibition of the CGRP receptor, which may affect the mechanism of headache.

Side Effects Management

Oropharyngeal Pain

Oropharyngeal pain may be caused by taking ubrogepant, but it is often mild and temporary. If you are concerned about oropharyngeal pain, please consult your doctor or pharmacist.

Nasopharyngitis

Nasopharyngitis may be caused by taking ubrogepant, but it is often mild and temporary. If you are concerned about nasopharyngitis, please consult your doctor or pharmacist.

Headache

Headache may be caused by taking ubrogepant, but it is often mild and temporary. If you are concerned about headache, please consult your doctor or pharmacist.

Research Comparisons

Research Commonalities

Multiple studies have shown that ubrogepant is effective in treating acute migraines. 9 7 2 Ubrogepant is generally well tolerated and serious side effects have been rarely reported.

Research Differences

There is still insufficient research on the long-term safety of ubrogepant. 1 There is also a lack of comparative research between ubrogepant and other migraine treatments.

Real-Life Application Considerations

Ubrogepant is an effective drug for treating acute migraines, but it is important to understand the risk of side effects. 7 When taking ubrogepant, consult your doctor or pharmacist and make sure you understand how to use it properly.

Limitations of Current Research

There is still insufficient research on the long-term safety of ubrogepant. 1 There is also a lack of comparative research between ubrogepant and other migraine treatments.

Future Research Directions

Research is needed to evaluate the long-term safety and efficacy of ubrogepant. Comparative studies between ubrogepant and other migraine treatments are also needed.

Conclusion

Ubrogepant is an effective drug for the acute treatment of migraine and is generally considered to be well tolerated. 7 However, it is important to understand the risk of side effects and consult your doctor or pharmacist to ensure proper use.

Literature analysis of 9 papers
Positive Content
7
Neutral Content
1
Negative Content
0
Article Type
1
1
1
4
9
3.

Ubrogepant and rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies.

Author: DongGuojun, KjærgaardNaoko Adachi, ShakibfarSaeed, SessaMaurizio

migraine treatment
ubrogerpant/rimegepant safety
ADRs

This study pooled estimates of the incidence of adverse drug reactions (ADRs) for ubrogepant and rimegepant and used meta-regression to identify correlations between ADRs and patient characteristics.

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

Gepants for Acute and Preventive Migraine Treatment: A Narrative Review.

Author: RissardoJamir Pitton, CapraraAna Letícia Fornari

Migraine prevention
Hemodynamic impairment

The new generation of CGRP antagonists, including rimegepant, ubrogepant, atogepant, and zavegepant, are effective for the acute and/or preventive treatment of migraines. While generally well-tolerated, long-term safety concerns remain, and careful pharmacovigilance is crucial. Further research is needed to assess their long-term effects and compare them with triptans, especially in elderly populations.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

7.

Ubrogepant to Treat Acute Migraine in Adults.

Author: EdinoffAmber N, CaseyC Austin, ColonMarc A, ZaheriAlexa R, GregoireCourtney M, BourgMargaret M, KayeAlan D, KayeJessica S, KayeAdam M, KayeRachel J, TirumalaSridhar R, ViswanathOmar, UritsIvan

Migraine treatment
Headache
Nasopharyngitis
Oropharyngeal pain

Ubrogepant is a new medication for the acute treatment of migraines with or without aura in adults. It has good tolerability and an overall favorable safety profile, with the most common side effects being oropharyngeal pain, nasopharyngitis, and headache. In most studies, participants taking Ubrogepant were free from pain within 2 hours compared to placebo. However, patients taking Ubrogepant should avoid taking it when pregnant or with end-stage renal disease.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.

Author: AilaniJessica, LiptonRichard B, HutchinsonSusan, KnievelKerry, LuKaifeng, ButlerMatthew, YuSung Yun, FinneganMichelle, SevertLawrence, TrugmanJoel M

Migraine treatment
Hepatic adverse events

Long-term intermittent use of ubrogepant 50 and 100 mg for the acute treatment of migraine was safe and well tolerated in a one-year trial. The incidence of treatment-related adverse events, serious adverse events, and discontinuations due to adverse events was low.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

9.

Targeting CGRP and 5-HT<sub>1F</sub> Receptors for the Acute Therapy of Migraine: A Literature Review.

Author: Moreno-AjonaDavid, ChanCalvin, Villar-MartínezMaría Dolores, GoadsbyPeter J

New migraine treatments
Targeted acute therapy

Emerging acute migraine treatments include CGRP receptor antagonists, gepants, and 5-HT1F receptor agonists. Phase III clinical trials of lasmiditan, rimegepant and ubrogepant met their primary endpoints, suggesting that the options for migraine-targeted acute therapy will soon increase.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.